<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<html>
 <body>
  <pubmedarticleset>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32292689
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Print">
        2211-3835
       </issn>
       <journalissue citedmedium="Print">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Feb
         </month>
         <day>
          27
         </day>
        </pubdate>
       </journalissue>
       <title>
        Acta pharmaceutica Sinica. B
       </title>
       <isoabbreviation>
        Acta Pharm Sin B
       </isoabbreviation>
      </journal>
      <articletitle>
       Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.apsb.2020.02.008
      </elocationid>
      <abstract>
       <abstracttext>
        SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further
        <i>
         in vitro
        </i>
        and
        <i>
         in vivo
        </i>
        studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.
       </abstracttext>
       <copyrightinformation>
        © 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Wu
        </lastname>
        <forename>
         Canrong
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Yang
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Yueying
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Peng
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhong
        </lastname>
        <forename>
         Wu
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Yali
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Qiqi
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xu
        </lastname>
        <forename>
         Yang
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Mingxue
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Xingzhou
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zheng
        </lastname>
        <forename>
         Mengzhu
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Lixia
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Hua
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design &amp; Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        27
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Acta Pharm Sin B
      </medlineta>
      <nlmuniqueid>
       101600560
      </nlmuniqueid>
      <issnlinking>
       2211-3835
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       3CLpro, 3-chymotrypsin-like protease
      </keyword>
      <keyword majortopicyn="N">
       Drug repurposing
      </keyword>
      <keyword majortopicyn="N">
       E, envelope
      </keyword>
      <keyword majortopicyn="N">
       Homology modeling
      </keyword>
      <keyword majortopicyn="N">
       M, membrane protein
      </keyword>
      <keyword majortopicyn="N">
       Molecular docking
      </keyword>
      <keyword majortopicyn="N">
       N, nucleocapsid protein
      </keyword>
      <keyword majortopicyn="N">
       Nsp, non-structure protein
      </keyword>
      <keyword majortopicyn="N">
       ORF, open reading frame
      </keyword>
      <keyword majortopicyn="N">
       PDB, protein data bank
      </keyword>
      <keyword majortopicyn="N">
       RdRp, RNA-dependence RNA polymerase
      </keyword>
      <keyword majortopicyn="N">
       Remdesivir
      </keyword>
      <keyword majortopicyn="N">
       S, Spike
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       SUD, SARS unique domain
      </keyword>
      <keyword majortopicyn="N">
       UB, ubiquitin-like domain
      </keyword>
     </keywordlist>
     <coistatement>
      The authors claim that the researchers in this study have no conflict of interest.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        12
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        17
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        18
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32292689
      </articleid>
      <articleid idtype="doi">
       10.1016/j.apsb.2020.02.008
      </articleid>
      <articleid idtype="pii">
       S2211-3835(20)30299-9
      </articleid>
      <articleid idtype="pmc">
       PMC7102550
      </articleid>
     </articleidlist>
     <?pmcsd ?>
     <referencelist>
      <reference>
       <citation>
        Virology. 2006 Jun 20;350(1):15-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16510163
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Comput Aided Mol Des. 2012 Jun;26(6):675-86
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22569591
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2013 Nov 28;503(7477):535-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24172901
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virus Res. 2015 Apr 16;202:120-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25445340
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2016 Jan 20;90(7):3627-39
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26792741
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochem Biophys Res Commun. 2008 Feb 15;366(3):738-44
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18082623
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Biol. 2005 Oct;3(10):e324
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16128623
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Exp Mol Pathol. 2020 Apr;113:104350
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31805278
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2012 Apr;4(4):557-80
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22590686
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2016 Jul 28;59(14):6595-628
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26878082
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2003 Aug;77(16):8801-11
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12885899
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841273
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2013 Oct;13(10):859-66
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23933067
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Dec;89(23):11820-33
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26378163
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chembiochem. 2008 Dec 15;9(18):3037-45
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19031435
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2013 Jul;87(14):7790-2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23678167
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Microbiol Rev. 2007 Oct;20(4):660-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17934078
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2015 Apr;89(7):3659-70
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25589660
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virus Res. 2014 Dec 19;194:200-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25451066
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antivir Chem Chemother. 2006;17(5):285-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17176633
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Chem Inf Model. 2012 Jul 23;52(7):1757-68
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22587354
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2004 Dec;78(24):13600-12
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15564471
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2004 Jul;78(14):7833-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15220459
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2003 May 15;348(20):1986-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12682352
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2016 May;15(5):327-47
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26868298
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2012 Nov 8;367(19):1814-20
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23075143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2008 May;82(9):4471-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18305050
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2003 Nov 27;426(6965):450-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14647384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2011 May;85(9):4122-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21325420
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        EMBO J. 2006 Oct 18;25(20):4933-42
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17024178
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12885-90
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16912115
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Protein Cell. 2014 May;5(5):369-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24622840
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2015 Jan 30;290(5):3172-82
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25505178
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14585926
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2014 Jan;101:122-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24269475
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4970-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24599590
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Infect. 2013 Dec;67(6):606-16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24096239
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 1999 Mar 11;42(5):791-804
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10072678
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16169905
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Sep 16;309(5742):1864-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16166518
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2014 Nov;14(11):1090-1095
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25278221
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W284-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15980471
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32291351
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Print">
        2379-5077
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         5
        </volume>
        <issue>
         2
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        mSystems
       </title>
       <isoabbreviation>
        mSystems
       </isoabbreviation>
      </journal>
      <articletitle>
       Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       e00297-20
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1128/mSystems.00297-20
      </elocationid>
      <abstract>
       <abstracttext>
        As of today (7 April 2020), more than 81,000 people around the world have died from the coronavirus disease 19 (COVID-19) pandemic. There is no approved drug or vaccine for COVID-19, although more than 10 clinical trials have been launched to test potential drugs. In an urgent response to this pandemic, I developed a bioinformatics pipeline to identify compounds and drug candidates to potentially treat COVID-19. This pipeline is based on publicly available single-cell RNA sequencing (scRNA-seq) data and the drug perturbation database "Library of Integrated Network-Based Cellular Signatures" (LINCS). I developed a ranking score system that prioritizes these drugs or small molecules. The four drugs with the highest total score are didanosine, benzyl-quinazolin-4-yl-amine, camptothecin, and RO-90-7501. In conclusion, I have demonstrated the utility of bioinformatics for identifying drugs than can be repurposed for potentially treating COVID-19 patients.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Alakwaa.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Alakwaa
        </lastname>
        <forename>
         Fadhl M
        </forename>
        <initials>
         FM
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-5349-7960
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA alakwaaf@med.umich.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       mSystems
      </medlineta>
      <nlmuniqueid>
       101680636
      </nlmuniqueid>
      <issnlinking>
       2379-5077
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       drug
      </keyword>
      <keyword majortopicyn="N">
       repurposing
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291351
      </articleid>
      <articleid idtype="pii">
       5/2/e00297-20
      </articleid>
      <articleid idtype="doi">
       10.1128/mSystems.00297-20
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32290293
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1422-0067
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         21
        </volume>
        <issue>
         7
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of molecular sciences
       </title>
       <isoabbreviation>
        Int J Mol Sci
       </isoabbreviation>
      </journal>
      <articletitle>
       A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       E2657
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.3390/ijms21072657
      </elocationid>
      <abstract>
       <abstracttext>
        The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a succinct overview of the epidemiology, clinical features, and molecular characteristics of SARS-CoV-2. We summarize the current epidemiological and clinical data from the initial Wuhan studies, and emphasize several features of SARS-CoV-2, which differentiate it from SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), such as high variability of disease presentation. We systematize the current clinical trials that have been rapidly initiated after the outbreak of COVID-19 pandemic. Whereas the trials on SARS-CoV-2 genome-based specific vaccines and therapeutic antibodies are currently being tested, this solution is more long-term, as they require thorough testing of their safety. On the other hand, the repurposing of the existing therapeutic agents previously designed for other virus infections and pathologies happens to be the only practical approach as a rapid response measure to the emergent pandemic, as most of these agents have already been tested for their safety. These agents can be divided into two broad categories, those that can directly target the virus replication cycle, and those based on immunotherapy approaches either aimed to boost innate antiviral immune responses or alleviate damage induced by dysregulated inflammatory responses. The initial clinical studies revealed the promising therapeutic potential of several of such drugs, including
        <i>
         favipiravir
        </i>
        , a broad-spectrum antiviral drug that interferes with the viral replication, and
        <i>
         hydroxychloroquine
        </i>
        , the repurposed antimalarial drug that interferes with the virus endosomal entry pathway. We speculate that the current pandemic emergency will be a trigger for more systematic drug repurposing design approaches based on big data analysis.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Tu
        </lastname>
        <forename>
         Yung-Fang
        </forename>
        <initials>
         YF
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chien
        </lastname>
        <forename>
         Chian-Shiu
        </forename>
        <initials>
         CS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yarmishyn
        </lastname>
        <forename>
         Aliaksandr A
        </forename>
        <initials>
         AA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Yi-Ying
        </forename>
        <initials>
         YY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Luo
        </lastname>
        <forename>
         Yung-Hung
        </forename>
        <initials>
         YH
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Chest Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Yi-Tsung
        </forename>
        <initials>
         YT
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lai
        </lastname>
        <forename>
         Wei-Yi
        </forename>
        <initials>
         WY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         De-Ming
        </forename>
        <initials>
         DM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chou
        </lastname>
        <forename>
         Shih-Jie
        </forename>
        <initials>
         SJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yang
        </lastname>
        <forename>
         Yi-Ping
        </forename>
        <initials>
         YP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Mong-Lien
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Food Safety and Health Risk Assessment, School of Pharmaceutical Sciences, National Yang Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chiou
        </lastname>
        <forename>
         Shih-Hwa
        </forename>
        <initials>
         SH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Genomic Research Center, Academia Sinica, Taipei 11529, Taiwan.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Switzerland
      </country>
      <medlineta>
       Int J Mol Sci
      </medlineta>
      <nlmuniqueid>
       101092791
      </nlmuniqueid>
      <issnlinking>
       1422-0067
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000998">
        Antiviral Agents
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000669933">
        COVID-19 vaccine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D007155">
        Immunologic Factors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D014765">
        Viral Vaccines
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705128">
       COVID-19 serotherapy
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000998">
        Antiviral Agents
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000235">
        genetics
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002986">
        Clinical Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000517">
        prevention &amp; control
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D016679">
        Genome, Viral
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007116">
        Immunization, Passive
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007155">
        Immunologic Factors
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D014765">
        Viral Vaccines
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACE2
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       clinical trials
      </keyword>
      <keyword majortopicyn="N">
       immunotherapy
      </keyword>
      <keyword majortopicyn="N">
       pneumonia
      </keyword>
      <keyword majortopicyn="N">
       replicase
      </keyword>
      <keyword majortopicyn="N">
       vaccine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        12
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        17
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32290293
      </articleid>
      <articleid idtype="pii">
       ijms21072657
      </articleid>
      <articleid idtype="doi">
       10.3390/ijms21072657
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32285930
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1532-6535
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical pharmacology and therapeutics
       </title>
       <isoabbreviation>
        Clin. Pharmacol. Ther.
       </isoabbreviation>
      </journal>
      <articletitle>
       Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/cpt.1856
      </elocationid>
      <abstract>
       <abstracttext>
        Hydroxychloroquine (HCQ) is a promising candidate for Coronavirus Disease of 2019 (COVID-19) treatment. The optimal dosing of HCQ is unknown. Our goal was to integrate historic and emerging pharmacological and toxicity data to understand safe and efficacious HCQ dosing strategies for COVID-19 treatment. The data sources included were 1) longitudinal clinical, pharmacokinetic, and virologic data from patients with severe acute respiratory syndrome-2 (SARS-CoV-2) infection who received HCQ with or without azithromycin (n=116), 2) in vitro viral replication data and SARS-CoV-2 viral load inhibition by HCQ, 3) a population pharmacokinetic model of HCQ and 4) a model relating chloroquine pharmacokinetics to QTc prolongation. A mechanistic PK/virologic/QTc model for HCQ was developed and externally validated to predict SARS-CoV-2 rate of viral decline and QTc prolongation. SARS-CoV-2 viral decline was associated with HCQ pharmacokinetics (p&lt;0.001). The extrapolated patient EC
        <sub>
         50
        </sub>
        was 4.7 µM, comparable to the reported in vitro EC
        <sub>
         50
        </sub>
        's. HCQ doses &gt; 400 mg BID for ≥5 days were predicted to rapidly decrease viral loads, reduce the proportion of patients with detectable SARS-CoV-2 infection, and shorten treatment courses, compared to lower dose (≤400 mg daily) regimens. However, HCQ doses &gt;600 mg BID were also predicted to prolong QTc intervals. This prolongation may have clinical implications warranting further safety assessment. Due to COVID-19's variable natural history, lower dose HCQ regimens may be indistinguishable from controls. Evaluation of higher HCQ doses is needed to ensure adequate safety and efficacy.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Garcia-Cremades
        </lastname>
        <forename>
         Maria
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Solans
        </lastname>
        <forename>
         Belen P
        </forename>
        <initials>
         BP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hughes
        </lastname>
        <forename>
         Emma
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ernest
        </lastname>
        <forename>
         Jacqueline P
        </forename>
        <initials>
         JP
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wallender
        </lastname>
        <forename>
         Erika
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Pharmacy, University of California, San Francisco, California, 94110, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Aweeka
        </lastname>
        <forename>
         Francesca
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Pharmacy, University of California, San Francisco, California, 94110, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Luetkemeyer
        </lastname>
        <forename>
         Annie
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Deprtment of Medicine, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Savic
        </lastname>
        <forename>
         Radojka M
        </forename>
        <initials>
         RM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, 94158, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Clin Pharmacol Ther
      </medlineta>
      <nlmuniqueid>
       0372741
      </nlmuniqueid>
      <issnlinking>
       0009-9236
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Infectious Disease
      </keyword>
      <keyword majortopicyn="N">
       Pharmacokinetics-pharmacodynamics
      </keyword>
      <keyword majortopicyn="N">
       Pharmacometrics
      </keyword>
      <keyword majortopicyn="N">
       Translational pharmacokinetics-pharmacodynamics
      </keyword>
      <keyword majortopicyn="N">
       Viral dynamics
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32285930
      </articleid>
      <articleid idtype="doi">
       10.1002/cpt.1856
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32280433
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Print">
        2001-0370
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         18
        </volume>
        <pubdate>
         <year>
          2020
         </year>
        </pubdate>
       </journalissue>
       <title>
        Computational and structural biotechnology journal
       </title>
       <isoabbreviation>
        Comput Struct Biotechnol J
       </isoabbreviation>
      </journal>
      <articletitle>
       Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.
      </articletitle>
      <pagination>
       <medlinepgn>
        784-790
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.csbj.2020.03.025
      </elocationid>
      <abstract>
       <abstracttext>
        The infection of a novel coronavirus found in Wuhan of China (SARS-CoV-2) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for SARS-CoV-2, various strategies are being tested in China, including drug repurposing. In this study, we used our pre-trained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of SARS-CoV-2. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing an inhibitory potency with
        <i>
         K
         <sub>
          d
         </sub>
        </i>
        of 94.94 nM against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of SARS-CoV-2 with an inhibitory potency with
        <i>
         K
         <sub>
          d
         </sub>
        </i>
        &lt; 1000 nM. In addition, we also found that several antiviral agents, such as Kaletra (lopinavir/ritonavir), could be used for the treatment of SARS-CoV-2. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for SARS-CoV-2.
       </abstracttext>
       <copyrightinformation>
        © 2020 The Authors.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Beck
        </lastname>
        <forename>
         Bo Ram
        </forename>
        <initials>
         BR
        </initials>
        <affiliationinfo>
         <affiliation>
          Deargen, Inc., Daejeon, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shin
        </lastname>
        <forename>
         Bonggun
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Deargen, Inc., Daejeon, Republic of Korea.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Computer Science, Emory University, Atlanta, GA, United States.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Choi
        </lastname>
        <forename>
         Yoonjung
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Deargen, Inc., Daejeon, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Park
        </lastname>
        <forename>
         Sungsoo
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Deargen, Inc., Daejeon, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kang
        </lastname>
        <forename>
         Keunsoo
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Microbiology, College of Natural Sciences, Dankook University, Cheonan, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Comput Struct Biotechnol J
      </medlineta>
      <nlmuniqueid>
       101585369
      </nlmuniqueid>
      <issnlinking>
       2001-0370
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Atazanavir
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Deep learning
      </keyword>
      <keyword majortopicyn="N">
       Drug repurposing
      </keyword>
      <keyword majortopicyn="N">
       MT-DTI
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
     <coistatement>
      Beck B.R., Choi Y., and Park S. are employed by company Deargen Inc. Shin B. is employed by Deargen Inc as a part-time advisor. Kang K. is one of the co-founders of, and a shareholder in, Deargen Inc.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        22
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        25
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32280433
      </articleid>
      <articleid idtype="doi">
       10.1016/j.csbj.2020.03.025
      </articleid>
      <articleid idtype="pii">
       S2001-0370(20)30049-0
      </articleid>
      <articleid idtype="pmc">
       PMC7118541
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32278811
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       12
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1872-7913
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          09
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of antimicrobial agents
       </title>
       <isoabbreviation>
        Int. J. Antimicrob. Agents
       </isoabbreviation>
      </journal>
      <articletitle>
       Drug repositioning an alternative for the treatment of coronavirus COVID-19.
      </articletitle>
      <pagination>
       <medlinepgn>
        105969
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0924-8579(20)30126-6
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.ijantimicag.2020.105969
      </elocationid>
      <abstract>
       <abstracttext>
        Given the extreme importance of the current pandemic caused by COVID-19, and due to the fact that scientists agree that there is no identified pharmacological treatment where possible therapeutic alternatives are raised through drug repositioning. We present a selection of studies involving drugs from different pharmaceutical classes with activity against SARS-CoV-2 and SARS-Cov, with potential use in the treatment of COVID-19 disease.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier Ltd. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Serafin
        </lastname>
        <forename>
         Marissa B
        </forename>
        <initials>
         MB
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bottega
        </lastname>
        <forename>
         Angelita
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Foletto
        </lastname>
        <forename>
         Vitória S
        </forename>
        <initials>
         VS
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         da Rosa
        </lastname>
        <forename>
         Taciéli F
        </forename>
        <initials>
         TF
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hörner
        </lastname>
        <forename>
         Andreas
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal de Santa Maria, Pós-Graduação Mestrado Profissional em Ciências da Saúde.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hörner
        </lastname>
        <forename>
         Rosmari
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil; Universidade Federal de Santa Maria, Departamento de Análises Clínicas e Toxicológicas, Santa Maria, RS, Brasil. Electronic address: rosmari.ufsm@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        09
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Int J Antimicrob Agents
      </medlineta>
      <nlmuniqueid>
       9111860
      </nlmuniqueid>
      <issnlinking>
       0924-8579
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Repositioning
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        19
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32278811
      </articleid>
      <articleid idtype="pii">
       S0924-8579(20)30126-6
      </articleid>
      <articleid idtype="doi">
       10.1016/j.ijantimicag.2020.105969
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32278693
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1879-0631
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         252
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          09
         </day>
        </pubdate>
       </journalissue>
       <title>
        Life sciences
       </title>
       <isoabbreviation>
        Life Sci.
       </isoabbreviation>
      </journal>
      <articletitle>
       In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.
      </articletitle>
      <pagination>
       <medlinepgn>
        117652
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0024-3205(20)30400-8
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.lfs.2020.117652
      </elocationid>
      <abstract>
       <abstracttext label="AIMS" nlmcategory="OBJECTIVE">
        The severe acute respiratory syndrome coronavirus 2, better known as COVID-19 has become the current health concern to the entire world. Initially appeared in Wuhan, China around December 2019, it had spread to almost 187 countries due to its high contagious nature. Precautionary measures remain the sole obliging tactic to cease the person to person transmissions till any effective method of treatment or vaccine is developed. Amidst the pandemic, research and development of new molecule is labour-intensive and tedious process. Drug repurposing is the concept of identifying therapeutically potent molecule from the library of pre-existing molecules.
       </abstracttext>
       <abstracttext label="MATERIALS AND METHODS" nlmcategory="METHODS">
        In the present study, 61 molecules that are already being used in clinics or under clinical scrutiny as antiviral agents are surveyed via docking study. Docking study was performed using Maestro interface (Schrödinger Suite, LLC, NY).
       </abstracttext>
       <abstracttext label="KEY FINDINGS" nlmcategory="RESULTS">
        Out of these 61 molecules, 37 molecules were found to interact with &gt;2 protein structures of COVID-19. The docking results indicate that amongst the reported molecules, HIV protease inhibitors and RNA-dependent RNA polymerase inhibitors showed promising features of binding to COVID-19 enzyme. Along with these, Methisazone an inhibitor of protein synthesis, CGP42112A an angiotensin AT2 receptor agonist and ABT450 an inhibitor of the non-structural protein 3-4A might become convenient treatment option as well against COVID-19.
       </abstracttext>
       <abstracttext label="SIGNIFICANCE" nlmcategory="CONCLUSIONS">
        The drug repurposing approach provide an insight about the therapeutics that might be helpful in treating corona virus disease.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier Inc. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Shah
        </lastname>
        <forename>
         Bhumi
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          L. J. Institute of Pharmacy, S. G. Highway, Sanand Circle, Sarkhej, Ahmedabad, Gujarat 382210, India; Registered Research Scholar K B Institute of Pharmaceutical Education and Research, Gandhinagar, Gujarat 382023, India. Electronic address: bhumi.shah_ljip@ljinstitutes.edu.in.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Modi
        </lastname>
        <forename>
         Palmi
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          L. J. Institute of Pharmacy, S. G. Highway, Sanand Circle, Sarkhej, Ahmedabad, Gujarat 382210, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sagar
        </lastname>
        <forename>
         Sneha R
        </forename>
        <initials>
         SR
        </initials>
        <affiliationinfo>
         <affiliation>
          L. J. Institute of Pharmacy, S. G. Highway, Sanand Circle, Sarkhej, Ahmedabad, Gujarat 382210, India.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        09
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Life Sci
      </medlineta>
      <nlmuniqueid>
       0375521
      </nlmuniqueid>
      <issnlinking>
       0024-3205
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Antiviral drugs
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Corona virus
      </keyword>
      <keyword majortopicyn="N">
       Docking studies
      </keyword>
      <keyword majortopicyn="N">
       MERS-CoV
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest The authors state no conflict of interest.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        05
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32278693
      </articleid>
      <articleid idtype="pii">
       S0024-3205(20)30400-8
      </articleid>
      <articleid idtype="doi">
       10.1016/j.lfs.2020.117652
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32271506
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1555-2101
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         81
        </volume>
        <issue>
         3
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          07
         </day>
        </pubdate>
       </journalissue>
       <title>
        The Journal of clinical psychiatry
       </title>
       <isoabbreviation>
        J Clin Psychiatry
       </isoabbreviation>
      </journal>
      <articletitle>
       "What Were You Before the War?" Repurposing Psychiatry During the COVID-19 Pandemic.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.4088/JCP.20com13373
      </elocationid>
      <elocationid eidtype="pii" validyn="Y">
       20com13373
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Nicol
        </lastname>
        <forename>
         Ginger E
        </forename>
        <initials>
         GE
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Psychiatry, Healthy Mind Laboratory, Washington University School of Medicine, 600 S. Taylor Ave, Ste 121, St Louis, MO 63110. nicolg@wustl.edu.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Karp
        </lastname>
        <forename>
         Jordan F
        </forename>
        <initials>
         JF
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Reiersen
        </lastname>
        <forename>
         Angela M
        </forename>
        <initials>
         AM
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Zorumski
        </lastname>
        <forename>
         Charles F
        </forename>
        <initials>
         CF
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Lenze
        </lastname>
        <forename>
         Eric J
        </forename>
        <initials>
         EJ
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Clin Psychiatry
      </medlineta>
      <nlmuniqueid>
       7801243
      </nlmuniqueid>
      <issnlinking>
       0160-6689
      </issnlinking>
     </medlinejournalinfo>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D002983">
        Clinical Competence
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002986">
        Clinical Trials as Topic
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000523">
        psychology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D058492">
        Drug Repositioning
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007400">
        Interprofessional Relations
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D008603">
        Mental Health
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008605">
        Mental Health Services
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000523">
        psychology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D024382">
        Professional Role
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011570">
        Psychiatry
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000639">
        trends
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012106">
        Research
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000639">
        trends
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D017216">
        Telemedicine
       </descriptorname>
      </meshheading>
     </meshheadinglist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32271506
      </articleid>
      <articleid idtype="doi">
       10.4088/JCP.20com13373
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32256547
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       09
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Electronic">
        1680-5348
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         44
        </volume>
        <pubdate>
         <year>
          2020
         </year>
        </pubdate>
       </journalissue>
       <title>
        Revista panamericana de salud publica = Pan American journal of public health
       </title>
       <isoabbreviation>
        Rev. Panam. Salud Publica
       </isoabbreviation>
      </journal>
      <articletitle>
       Clinical trials on drug repositioning for COVID-19 treatment.
      </articletitle>
      <pagination>
       <medlinepgn>
        e40
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.26633/RPSP.2020.40
      </elocationid>
      <abstract>
       <abstracttext>
        The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus
        <i>
         Betacoronavirus
        </i>
        , that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Rosa
        </lastname>
        <forename>
         Sandro G Viveiros
        </forename>
        <initials>
         SGV
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Santos
        </lastname>
        <forename>
         Wilson C
        </forename>
        <initials>
         WC
        </initials>
        <affiliationinfo>
         <affiliation>
          Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        20
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Rev Panam Salud Publica
      </medlineta>
      <nlmuniqueid>
       9705400
      </nlmuniqueid>
      <issnlinking>
       1020-4989
      </issnlinking>
     </medlinejournalinfo>
     <otherabstract language="spa" type="Publisher">
      <abstracttext>
       En diciembre de 2019 fue informado a la Organización Mundial de la Salud (OMS) un brote de neumonía por coronavirus en Wuhan, provincia de Hubei, China. Al 12 de marzo de 2020, se habían notificado 125 048 casos y 4 614 muertes. El coronavirus es un virus ARN envuelto del género
       <i>
        Betacoronavirus
       </i>
       distribuido en aves, seres humanos y otros mamíferos. La OMS ha denominado a la nueva enfermedad por coronavirus COVID-19. Se han puesto en marcha más de 80 ensayos clínicos para evaluar un tratamiento para el coronavirus, que incluyen algunos ensayos de reposicionamiento de medicamentos para la COVID-19. En marzo de 2020 se llevó a cabo una búsqueda de los ensayos clínicos registrados en la base de datos clinicaltrials.gov. Los criterios de elegibilidad para los estudios recuperados fueron tener un número de identificación de la base de datos clinicaltrials.gov; describir el número de participantes y el período del estudio; describir las condiciones clínicas de los participantes; y emplear intervenciones con medicamentos ya estudiados o aprobados para cualquier otra enfermedad en pacientes infectados con el nuevo coronavirus SARS-CoV-2 (2019-nCoV). Es esencial destacar que este artículo solo recoge los ensayos que figuran en la base de datos clinicaltrials. gov. Se identificaron 24 ensayos clínicos relacionados con más de 20 medicamentos, como inmunoglobulina humana, interferones, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumab y medicina tradicional china. Aunque el reposicionamiento de medicamentos tiene algunas limitaciones, el reposicionamiento de los ensayos clínicos puede representar una estrategia atractiva porque facilita el descubrimiento de nuevas clases de medicamentos; estos tienen costos más bajos y tardan menos en llegar al mercado; y existen cadenas de suministro farmacéutico que apoyan la formulación y la distribución.
      </abstracttext>
     </otherabstract>
     <otherabstract language="por" type="Publisher">
      <abstracttext>
       A Organização Mundial da Saúde (OMS) foi informada, em dezembro de 2019, sobre um surto de pneumonia por coronavírus em Wuhan, província de Hubei (China). Posteriormente, em 12 de março de 2020, 125 048 casos e 4 614 mortes haviam sido registrados. O coronavírus é um vírus RNA envelopado do gênero
       <i>
        Betacoronavírus,
       </i>
       distribuído em aves e em humanos e outros mamíferos. A OMS designou a nova doença por coronavírus como COVID-19. Mais de 80 ensaios clínicos foram iniciados para testar tratamentos para o coronavírus, incluindo alguns de reposicionamento de medicamentos para o COVID-19. Assim, em março de 2020 realizou-se uma busca na base de dados clinicaltrials.gov. Os critérios de elegibilidade para os estudos recuperados foram: conter o número identificador da base de dados clinicaltrials.gov; descrever o número de participantes e o período do estudo; descrever as condições clínicas dos participantes; e utilizar intervenções para tratamento de doentes infectados com o novo coronavírus SARS-CoV-2 (2019-nCoV) com medicamentos já estudados ou aprovados para qualquer outra doença. É essencial salientar que este artigo apenas capturou ensaios listados na base de dados clinicaltrials.gov. Foram identificados 24 ensaios clínicos envolvendo mais de 20 medicamentos, tais como imunoglobulina humana, interferons, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumabe e medicamentos chineses tradicionais. Embora o reposicionamento de medicamentos tenha algumas limitações, os ensaios clínicos de reposicionamento podem representar uma estratégia atraente, porque facilitam a descoberta de novas classes de medicamentos, têm custos mais baixos, levam menos tempo para chegar ao mercado e se beneficiam de cadeias de fornecimento farmacêutico já existentes para formulação e distribuição.
      </abstracttext>
     </otherabstract>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Drug repositioning
      </keyword>
      <keyword majortopicyn="N">
       clinical trials as topic
      </keyword>
      <keyword majortopicyn="N">
       coronavirus infection
      </keyword>
      <keyword majortopicyn="N">
       pandemics
      </keyword>
      <keyword majortopicyn="N">
       pneumonia, viral
      </keyword>
      <keyword majortopicyn="N">
       virus diseases
      </keyword>
     </keywordlist>
     <coistatement>
      Conflicts of interest. None declared.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        19
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        20
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        8
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32256547
      </articleid>
      <articleid idtype="doi">
       10.26633/RPSP.2020.40
      </articleid>
      <articleid idtype="pii">
       RPSP.2020.40
      </articleid>
      <articleid idtype="pmc">
       PMC7105280
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        J Clin Virol. 2004 Dec;31(4):304-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15494274
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2014 Jul;107:84-94
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24769245
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Autoimmun Rev. 2016 Jan;15(1):71-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26384525
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Discov Today. 2019 Mar;24(3):726-736
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30711575
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trials. 2018 Jan 30;19(1):81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29382391
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 20;:105949
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32205204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2019 Aug 13;366:l5140
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31409588
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 18;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32187464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Pharmacol Ther. 2010 Mar;87(3):322-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20043009
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Anticancer Res. 2019 Nov;39(11):5891-5901
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31704813
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trends Microbiol. 2018 Oct;26(10):865-876
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29759926
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Chin Med. 2019;47(6):1223-1235
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31505937
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        AIDS Res Hum Retroviruses. 2019 Jun;35(6):513-518
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30909716
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Annu Rev Immunol. 2014;32:513-45
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24555472
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Discov Today. 2019 Jan;24(1):1-3
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29936247
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2019 Jan;18(1):41-58
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30310233
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2007 Oct;30(4):297-308
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17629679
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2018 May 2;66(10):1501-1503
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29315362
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2020 Mar;19(3):149-150
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32127666
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Angiogenesis. 2004;7(4):335-45
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15886877
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drugs. 2018 Aug;78(12):1271-1276
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30117020
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nutrients. 2020 Jan 22;12(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31978969
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4956-4961
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30070331
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 7;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32031570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 5;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32022836
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2003 Oct 25;362(9393):1353-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14585636
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2162-2164
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32141586
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Expert Rev Anti Infect Ther. 2017 Mar;15(3):269-275
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27937060
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32251731
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1872-7913
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          03
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of antimicrobial agents
       </title>
       <isoabbreviation>
        Int. J. Antimicrob. Agents
       </isoabbreviation>
      </journal>
      <articletitle>
       Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
      </articletitle>
      <pagination>
       <medlinepgn>
        105960
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0924-8579(20)30110-2
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.ijantimicag.2020.105960
      </elocationid>
      <abstract>
       <abstracttext>
        The recent emergence of the novel pathogenic SARS-coronavirus 2 (SARS-CoV-2) is responsible for a worldwide pandemic. Given the global health emergency, drug repositioning is the most reliable option to design an efficient therapy for infected patients without delay. The first step of the viral replication cycle [i.e. attachment to the surface of respiratory cells, mediated by the spike (S) viral protein] offers several potential therapeutic targets. The S protein uses the angiotension-converting enzyme-2 (ACE-2) receptor for entry, but also sialic acids linked to host cell surface gangliosides. Using a combination of structural and molecular modelling approaches, this study showed that chloroquine (CLQ), one of the drugs currently under investigation for SARS-CoV-2 treatment, binds sialic acids and gangliosides with high affinity. A new type of ganglioside-binding domain at the tip of the N-terminal domain of the SARS-CoV-2 S protein was identified. This domain (111-158), which is fully conserved among clinical isolates worldwide, may improve attachment of the virus to lipid rafts and facilitate contact with the ACE-2 receptor. This study showed that, in the presence of CLQ [or its more active derivative, hydroxychloroquine (CLQ-OH)], the viral S protein is no longer able to bind gangliosides. The identification of this new mechanism of action of CLQ and CLQ-OH supports the use of these repositioned drugs to cure patients infected with SARS-CoV-2. The in-silico approaches used in this study might also be used to assess the efficiency of a broad range of repositioned and/or innovative drug candidates before clinical evaluation.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Fantini
        </lastname>
        <forename>
         Jacques
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          INSERM UMR_S 1072, Marseille, France; Department of Biology, Aix-Marseille Université, Marseille, France. Electronic address: jacques.fantini@univ-amu.fr.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Di Scala
        </lastname>
        <forename>
         Coralie
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          INMED, INSERM U1249, Parc Scientifique de Luminy, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chahinian
        </lastname>
        <forename>
         Henri
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          INSERM UMR_S 1072, Marseille, France; Department of Biology, Aix-Marseille Université, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yahi
        </lastname>
        <forename>
         Nouara
        </forename>
        <initials>
         N
        </initials>
        <affiliationinfo>
         <affiliation>
          INSERM UMR_S 1072, Marseille, France; Department of Biology, Aix-Marseille Université, Marseille, France.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        03
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Int J Antimicrob Agents
      </medlineta>
      <nlmuniqueid>
       9111860
      </nlmuniqueid>
      <issnlinking>
       0924-8579
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Chloroquine
      </keyword>
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       Ganglioside
      </keyword>
      <keyword majortopicyn="N">
       Pandemic
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Spike
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        16
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        21
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        7
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        7
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        7
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32251731
      </articleid>
      <articleid idtype="pii">
       S0924-8579(20)30110-2
      </articleid>
      <articleid idtype="doi">
       10.1016/j.ijantimicag.2020.105960
      </articleid>
      <articleid idtype="pmc">
       PMC7128678
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32239142
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       02
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1367-4811
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          01
         </day>
        </pubdate>
       </journalissue>
       <title>
        Bioinformatics (Oxford, England)
       </title>
       <isoabbreviation>
        Bioinformatics
       </isoabbreviation>
      </journal>
      <articletitle>
       Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       btaa224
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1093/bioinformatics/btaa224
      </elocationid>
      <abstract>
       <abstracttext label="MOTIVATION" nlmcategory="BACKGROUND">
        Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70,000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency, and patient burden. We recently developed a computational protocol named as SCAR for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least 6 hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19.
       </abstracttext>
       <copyrightinformation>
        © The Author(s) (2020). Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Sen
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Industrial Fermentation (Ministry of Education), Hubei University of Technology, Wuhan, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Biomedical and Pharmaceutical Sciences, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zheng
        </lastname>
        <forename>
         Qiang
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Industrial Fermentation (Ministry of Education), Hubei University of Technology, Wuhan, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Biomedical and Pharmaceutical Sciences, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Zhiying
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Industrial Fermentation (Ministry of Education), Hubei University of Technology, Wuhan, China.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Institute of Biomedical and Pharmaceutical Sciences, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Bioinformatics
      </medlineta>
      <nlmuniqueid>
       9808944
      </nlmuniqueid>
      <issnlinking>
       1367-4803
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        21
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        15
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        25
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32239142
      </articleid>
      <articleid idtype="pii">
       5814924
      </articleid>
      <articleid idtype="doi">
       10.1093/bioinformatics/btaa224
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32238757
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       10
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       10
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Electronic">
        1738-8872
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         30
        </volume>
        <issue>
         3
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          28
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of microbiology and biotechnology
       </title>
       <isoabbreviation>
        J. Microbiol. Biotechnol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19).
      </articletitle>
      <pagination>
       <medlinepgn>
        313-324
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.4014/jmb.2003.03011
      </elocationid>
      <abstract>
       <abstracttext>
        Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Ahn
        </lastname>
        <forename>
         Dae-Gyun
        </forename>
        <initials>
         DG
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shin
        </lastname>
        <forename>
         Hye-Jin
        </forename>
        <initials>
         HJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kim
        </lastname>
        <forename>
         Mi-Hwa
        </forename>
        <initials>
         MH
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Bioenvironmental Science and Toxicology Division, Gyeongnam Branch Institute, Korea Institute of Toxicology, Jinju 52834, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lee
        </lastname>
        <forename>
         Sunhee
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kim
        </lastname>
        <forename>
         Hae-Soo
        </forename>
        <initials>
         HS
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Myoung
        </lastname>
        <forename>
         Jinjong
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Korea Zoonosis Research Institute and Genetic Engineering Research Institute, Jeonbuk National University, Jeollabuk-do 54896, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kim
        </lastname>
        <forename>
         Bum-Tae
        </forename>
        <initials>
         BT
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kim
        </lastname>
        <forename>
         Seong-Jun
        </forename>
        <initials>
         SJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       Korea (South)
      </country>
      <medlineta>
       J Microbiol Biotechnol
      </medlineta>
      <nlmuniqueid>
       9431852
      </nlmuniqueid>
      <issnlinking>
       1017-7825
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000669933">
        COVID-19 vaccine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D014765">
        Viral Vaccines
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000657964">
       COVID-19 diagnostic testing
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D019411">
        Clinical Laboratory Techniques
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000517">
        prevention &amp; control
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000453">
        epidemiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000628">
        therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D014765">
        Viral Vaccines
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       coronavirus
      </keyword>
      <keyword majortopicyn="N">
       outbreak
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        11
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32238757
      </articleid>
      <articleid idtype="pii">
       10.4014/jmb.2003.03011
      </articleid>
      <articleid idtype="doi">
       10.4014/jmb.2003.03011
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32238094
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1538-0254
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of biomolecular structure &amp; dynamics
       </title>
       <isoabbreviation>
        J. Biomol. Struct. Dyn.
       </isoabbreviation>
      </journal>
      <articletitle>
       Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
       <i>
        via
       </i>
       integrated computational approach.
      </articletitle>
      <pagination>
       <medlinepgn>
        1-10
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1080/07391102.2020.1751298
      </elocationid>
      <abstract>
       <abstracttext>
        Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL
        <sup>
         pro
        </sup>
        ) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs (Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL
        <sup>
         pro
        </sup>
        ) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.Communicated by Ramaswamy H. Sarma.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Khan
        </lastname>
        <forename>
         Salman Ali
        </forename>
        <initials>
         SA
        </initials>
        <affiliationinfo>
         <affiliation>
          Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zia
        </lastname>
        <forename>
         Komal
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ashraf
        </lastname>
        <forename>
         Sajda
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Uddin
        </lastname>
        <forename>
         Reaz
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ul-Haq
        </lastname>
        <forename>
         Zaheer
        </forename>
        <initials>
         Z
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-8530-8711
        </identifier>
        <affiliationinfo>
         <affiliation>
          Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          H.E.J Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       J Biomol Struct Dyn
      </medlineta>
      <nlmuniqueid>
       8404176
      </nlmuniqueid>
      <issnlinking>
       0739-1102
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       3CLpro
      </keyword>
      <keyword majortopicyn="N">
       MD simulation
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       corona virus
      </keyword>
      <keyword majortopicyn="N">
       drug repurposing
      </keyword>
      <keyword majortopicyn="N">
       remdesivir
      </keyword>
      <keyword majortopicyn="N">
       virtual screening
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        3
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32238094
      </articleid>
      <articleid idtype="doi">
       10.1080/07391102.2020.1751298
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32222463
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       04
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1879-0631
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          25
         </day>
        </pubdate>
       </journalissue>
       <title>
        Life sciences
       </title>
       <isoabbreviation>
        Life Sci.
       </isoabbreviation>
      </journal>
      <articletitle>
       Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
      </articletitle>
      <pagination>
       <medlinepgn>
        117592
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0024-3205(20)30340-4
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.lfs.2020.117592
      </elocationid>
      <abstract>
       <abstracttext label="AIMS" nlmcategory="OBJECTIVE">
        A new human coronavirus (HCoV), which has been designated SARS-CoV-2, began spreading in December 2019 in Wuhan City, China causing pneumonia called COVID-19. The spread of SARS-CoV-2 has been faster than any other coronaviruses that have succeeded in crossing the animal-human barrier. There is concern that this new virus will spread around the world as did the previous two HCoVs-Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)-each of which caused approximately 800 deaths in the years 2002 and 2012, respectively. Thus far, 11,268 deaths have been reported from the 258,842 confirmed infections in 168 countries.
       </abstracttext>
       <abstracttext label="MAIN METHODS" nlmcategory="METHODS">
        In this study, the RNA-dependent RNA polymerase (RdRp) of the newly emerged coronavirus is modeled, validated, and then targeted using different anti-polymerase drugs currently on the market that have been approved for use against various viruses.
       </abstracttext>
       <abstracttext label="KEY FINDINGS" nlmcategory="RESULTS">
        The results suggest the effectiveness of Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir as potent drugs against SARS-CoV-2 since they tightly bind to its RdRp. In addition, the results suggest guanosine derivative (IDX-184), Setrobuvir, and YAK as top seeds for antiviral treatments with high potential to fight the SARS-CoV-2 strain specifically.
       </abstracttext>
       <abstracttext label="SIGNIFICANCE" nlmcategory="CONCLUSIONS">
        The availability of FDA-approved anti-RdRp drugs can help treat patients and reduce the danger of the mysterious new viral infection COVID-19. The drugs mentioned above can tightly bind to the RdRp of the SARS-CoV-2 strain and thus may be used to treat the disease. No toxicity measurements are required for these drugs since they were previously tested prior to their approval by the FDA.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020. Published by Elsevier Inc.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Elfiky
        </lastname>
        <forename>
         Abdo A
        </forename>
        <initials>
         AA
        </initials>
        <affiliationinfo>
         <affiliation>
          Biophysics Department, Faculty of Sciences, Cairo University, Giza, Egypt. Electronic address: abdo@sci.cu.edu.eg.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        25
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Life Sci
      </medlineta>
      <nlmuniqueid>
       0375521
      </nlmuniqueid>
      <issnlinking>
       0024-3205
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Drug repurposing
      </keyword>
      <keyword majortopicyn="N">
       Molecular docking
      </keyword>
      <keyword majortopicyn="N">
       RdRp
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Structural bioinformatics
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of competing interest The author declares that there is no competing interest in this work.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        20
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        31
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        31
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        31
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32222463
      </articleid>
      <articleid idtype="pii">
       S0024-3205(20)30340-4
      </articleid>
      <articleid idtype="doi">
       10.1016/j.lfs.2020.117592
      </articleid>
      <articleid idtype="pmc">
       PMC7102646
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2018 Jan;90(1):13-18
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28922464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochem Biophys Res Commun. 2012 Aug 24;425(2):485-92
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22877750
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Comput Chem. 2009 Dec;30(16):2785-91
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19399780
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2017 Jun;89(6):1040-1047
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27864902
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Comput Chem. 2010 Jan 30;31(2):455-61
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19499576
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Opin Struct Biol. 1998 Dec;8(6):704-12
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9914251
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Med Chem. 2019;15(2):130-137
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30324891
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2016 Dec;88(12):2044-2051
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27604059
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Protein Sci. 2018 Jan;27(1):293-315
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29067766
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 1996 May 23;381(6580):272
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8692262
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Med Chem Res. 2016;25(5):1005-1008
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32214769
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Microbiol Rev. 2015 Apr;28(2):465-522
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25810418
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2019 May 28;10(1):2342
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31138817
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2014 Nov;88(21):12511-27
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25142582
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Mol Biol. 1996 Nov 22;264(1):121-36
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         8950272
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        SAR QSAR Environ Res. 2018 May;29(5):409-418
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29652194
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Mol Model. 2007 Dec;13(12):1173-213
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17828561
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biomol NMR. 1996 Dec;8(4):477-86
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         9008363
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Infect Dis. 2020 Feb;91:264-266
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31953166
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Protein J. 2013 Jan;32(1):75-80
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23322006
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32216577
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       10
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       10
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1531-2267
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         52
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          01
         </day>
        </pubdate>
       </journalissue>
       <title>
        Physiological genomics
       </title>
       <isoabbreviation>
        Physiol. Genomics
       </isoabbreviation>
      </journal>
      <articletitle>
       Artificial intelligence and machine learning to fight COVID-19.
      </articletitle>
      <pagination>
       <medlinepgn>
        200-202
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1152/physiolgenomics.00029.2020
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Alimadadi
        </lastname>
        <forename>
         Ahmad
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Hypertension and Precision Medicine, Program in Physiological Genomics, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Aryal
        </lastname>
        <forename>
         Sachin
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Hypertension and Precision Medicine, Program in Physiological Genomics, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Manandhar
        </lastname>
        <forename>
         Ishan
        </forename>
        <initials>
         I
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Hypertension and Precision Medicine, Program in Physiological Genomics, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Munroe
        </lastname>
        <forename>
         Patricia B
        </forename>
        <initials>
         PB
        </initials>
        <identifier source="ORCID">
         0000-0002-4176-2947
        </identifier>
        <affiliationinfo>
         <affiliation>
          Center for Hypertension and Precision Medicine, Program in Physiological Genomics, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Clinical Pharmacology, William Harvey Research Institute, National Institute of Health Research Barts Cardiovascular Biomedical Research Centre, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Joe
        </lastname>
        <forename>
         Bina
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Hypertension and Precision Medicine, Program in Physiological Genomics, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cheng
        </lastname>
        <forename>
         Xi
        </forename>
        <initials>
         X
        </initials>
        <identifier source="ORCID">
         0000-0002-0838-5094
        </identifier>
        <affiliationinfo>
         <affiliation>
          Center for Hypertension and Precision Medicine, Program in Physiological Genomics, Department of Physiology and Pharmacology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         R01 HL143082
        </grantid>
        <acronym>
         HL
        </acronym>
        <agency>
         NHLBI NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
       <publicationtype ui="D052061">
        Research Support, N.I.H., Extramural
       </publicationtype>
       <publicationtype ui="D013485">
        Research Support, Non-U.S. Gov't
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        27
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Physiol Genomics
      </medlineta>
      <nlmuniqueid>
       9815683
      </nlmuniqueid>
      <issnlinking>
       1094-8341
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000669933">
        COVID-19 vaccine
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D014765">
        Viral Vaccines
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D001185">
        Artificial Intelligence
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000517">
        prevention &amp; control
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000628">
        therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004198">
        Disease Susceptibility
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000175">
        diagnosis
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000076722">
        Drug Development
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000592">
        standards
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000639">
        trends
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058492">
        Drug Repositioning
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000592">
        standards
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000069550">
        Machine Learning
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000517">
        prevention &amp; control
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000517">
        prevention &amp; control
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000628">
        therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D014765">
        Viral Vaccines
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000032">
        analysis
       </qualifiername>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="Y">
       artificial intelligence
      </keyword>
      <keyword majortopicyn="Y">
       machine learning
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        29
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        11
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        29
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32216577
      </articleid>
      <articleid idtype="doi">
       10.1152/physiolgenomics.00029.2020
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Data-Review">
     <pmid version="1">
      32205870
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       09
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Electronic">
        1546-1696
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         38
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
        </pubdate>
       </journalissue>
       <title>
        Nature biotechnology
       </title>
       <isoabbreviation>
        Nat. Biotechnol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Coronavirus puts drug repurposing on the fast track.
      </articletitle>
      <pagination>
       <medlinepgn>
        379-381
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1038/d41587-020-00003-1
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Harrison
        </lastname>
        <forename>
         Charlotte
        </forename>
        <initials>
         C
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016433">
        News
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Nat Biotechnol
      </medlineta>
      <nlmuniqueid>
       9604648
      </nlmuniqueid>
      <issnlinking>
       1087-0156
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        25
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        25
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        25
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32205870
      </articleid>
      <articleid idtype="doi">
       10.1038/d41587-020-00003-1
      </articleid>
      <articleid idtype="pii">
       10.1038/d41587-020-00003-1
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32194980
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       09
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Print">
        2056-5968
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         6
        </volume>
        <pubdate>
         <year>
          2020
         </year>
        </pubdate>
       </journalissue>
       <title>
        Cell discovery
       </title>
       <isoabbreviation>
        Cell Discov
       </isoabbreviation>
      </journal>
      <articletitle>
       Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.
      </articletitle>
      <pagination>
       <medlinepgn>
        14
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1038/s41421-020-0153-3
      </elocationid>
      <abstract>
       <abstracttext>
        Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV-host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the "
        <i>
         Complementary Exposure
        </i>
        " pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.
       </abstracttext>
       <copyrightinformation>
        © The Author(s) 2020.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author equalcontrib="Y" validyn="Y">
        <lastname>
         Zhou
        </lastname>
        <forename>
         Yadi
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA.
         </affiliation>
         <identifier source="ISNI">
          0000 0001 0675 4725
         </identifier>
         <identifier source="GRID">
          grid.239578.2
         </identifier>
        </affiliationinfo>
       </author>
       <author equalcontrib="Y" validyn="Y">
        <lastname>
         Hou
        </lastname>
        <forename>
         Yuan
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA.
         </affiliation>
         <identifier source="ISNI">
          0000 0001 0675 4725
         </identifier>
         <identifier source="GRID">
          grid.239578.2
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shen
        </lastname>
        <forename>
         Jiayu
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA.
         </affiliation>
         <identifier source="ISNI">
          0000 0001 0675 4725
         </identifier>
         <identifier source="GRID">
          grid.239578.2
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Yin
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA.
         </affiliation>
         <identifier source="ISNI">
          0000 0001 0675 4725
         </identifier>
         <identifier source="GRID">
          grid.239578.2
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Martin
        </lastname>
        <forename>
         William
        </forename>
        <initials>
         W
        </initials>
        <identifier source="ORCID">
         0000-0003-0616-0462
        </identifier>
        <affiliationinfo>
         <affiliation>
          1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA.
         </affiliation>
         <identifier source="ISNI">
          0000 0001 0675 4725
         </identifier>
         <identifier source="GRID">
          grid.239578.2
         </identifier>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cheng
        </lastname>
        <forename>
         Feixiong
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195 USA.
         </affiliation>
         <identifier source="ISNI">
          0000 0001 0675 4725
         </identifier>
         <identifier source="GRID">
          grid.239578.2
         </identifier>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195 USA.
         </affiliation>
         <identifier source="ISNI">
          0000 0001 2164 3847
         </identifier>
         <identifier source="GRID">
          grid.67105.35
         </identifier>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106 USA.
         </affiliation>
         <identifier source="ISNI">
          0000 0001 2164 3847
         </identifier>
         <identifier source="GRID">
          grid.67105.35
         </identifier>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <grantlist completeyn="Y">
       <grant>
        <grantid>
         K99 HL138272
        </grantid>
        <acronym>
         HL
        </acronym>
        <agency>
         NHLBI NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
       <grant>
        <grantid>
         R00 HL138272
        </grantid>
        <acronym>
         HL
        </acronym>
        <agency>
         NHLBI NIH HHS
        </agency>
        <country>
         United States
        </country>
       </grant>
      </grantlist>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Cell Discov
      </medlineta>
      <nlmuniqueid>
       101661034
      </nlmuniqueid>
      <issnlinking>
       2056-5968
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Bioinformatics
      </keyword>
      <keyword majortopicyn="N">
       Comparative genomics
      </keyword>
      <keyword majortopicyn="N">
       Proteomic analysis
      </keyword>
     </keywordlist>
     <coistatement>
      Conflict of interestThe authors declare that they have no conflict of interest.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        05
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        02
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        21
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        21
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        21
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32194980
      </articleid>
      <articleid idtype="doi">
       10.1038/s41421-020-0153-3
      </articleid>
      <articleid idtype="pii">
       153
      </articleid>
      <articleid idtype="pmc">
       PMC7073332
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 22;395(10224):565-574
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007145
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2019 Mar 13;10(1):1197
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30867426
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2019 May 28;10(1):2342
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31138817
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Asia Pac Allergy. 2013 Apr;3(2):136-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23667838
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2013 Sep;87(17):9486-500
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23637410
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trends Microbiol. 2017 Jan;25(1):35-48
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27743750
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841273
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Discov Med. 2010 Dec;10(55):479-88
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21189219
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):270-273
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2020 Mar 13;367(6483):1260-1263
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32075877
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29722887
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Breast Cancer Res Treat. 2011 Aug;128(3):625-31
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21553116
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antivir Chem Chemother. 2009;19(4):151-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19374142
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2018 Jul 12;9(1):2691
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30002366
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hum Genet. 2019 May 2;104(5):861-878
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31006514
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Pineal Res. 2007 Jan;42(1):28-42
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17198536
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Top Microbiol Immunol. 2018;419:1-42
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28643204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Inflammopharmacology. 2006 Mar;14(1-2):2-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16835706
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Sci (Lond). 2006 Mar;110(3):379-86
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16336207
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2002 May;76(10):5233-50
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         11967337
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Pineal Res. 2014 Nov;57(4):381-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25262626
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        FEBS Lett. 2008 Jan 23;582(2):385-90
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18070603
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Bioinformatics. 2020 Jan 23;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31971579
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2013 Jan;87(2):912-22
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23135723
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2016 May;15(5):327-47
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26868298
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2014 Jan;42(Database issue):D1091-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24203711
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Pharmacol Ther. 2018 Feb;103(2):287-295
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29052226
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drugs. 2017 Dec;77(18):1935-1966
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29143192
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Elife. 2019 Jan 11;8:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30632963
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Transl Med. 2015 Apr 8;7(282):282ra49
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25855495
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2016 Jan 4;44(D1):D7-19
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26615191
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Pineal Res. 2013 Apr;54(3):245-57
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22998574
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Naunyn Schmiedebergs Arch Pharmacol. 2016 Jul;389(7):695-712
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27146293
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antivir Ther. 2015;20(8):835-42
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25929767
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        mSystems. 2019 Apr 9;4(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30984872
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS One. 2013 May 23;8(5):e65045
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23717688
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2017 Jan;16(1):19-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27910877
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Top Med Chem. 2004;4(13):1433-54
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15379656
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2019 Aug 2;10(1):3476
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31375661
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Brief Funct Genomics. 2018 Nov 26;17(6):381-391
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29028879
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2014 Jan;42(Database issue):D1098-106
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24234439
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ital J Pediatr. 2013 Oct 03;39:61
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24090288
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Respir Med Case Rep. 2017 Apr 12;21:116-117
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28458997
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        mBio. 2013 Apr 30;4(3):e00165-13
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23631916
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Death Dis. 2017 Dec 13;8(12):3215
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29238080
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trends Mol Med. 2016 Nov;22(11):919-921
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27692879
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Recent Pat Endocr Metab Immune Drug Discov. 2012 Jan;6(1):30-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22264213
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur J Heart Fail. 2009 Apr;11(4):349-53
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19213804
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Host Microbe. 2016 Aug 10;20(2):259-70
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27476412
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2004 Jan 1;32(Database issue):D115-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14681372
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Gen Virol. 1992 Dec;73 ( Pt 12):3285-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         1335030
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2019 Jan 10;10(1):120
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30631056
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2017 Jan;137:76-81
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27864075
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21948594
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Jan 29;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31995857
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Comput Biol. 2012;8(5):e1002503
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22589709
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Med. 2016 Oct;22(10):1101-1107
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27571349
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Microbiol. 2016 Aug;14(8):523-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27344959
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2017 Nov 29;65(12):2042-2049
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29020174
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2015 Aug;120:140-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26086883
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Sep 16;309(5742):1864-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16166518
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Bioinformatics. 2019 Dec 15;35(24):5191-5198
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31116390
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2019 Sep 5;178(6):1526-1541.e16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31474372
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Biotechnol. 2012 Nov;30(11):1125-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23064238
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2015 Mar;115:9-16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25542975
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841269
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2007 May;74(2):92-101
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16730806
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Gut. 2016 Dec;65(12):2017-2028
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26276683
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27141961
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Pineal Res. 2002 Mar;32(2):112-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12071468
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Transl Med. 2013 Jun 19;5(190):190ra79
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23785035
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2017 Dec 21;377(25):2493-2499
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29262277
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Transl Med. 2011 Aug 17;3(96):96ra77
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21849665
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2007 Jan;35(Database issue):D198-201
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17145705
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Crit Care Med. 2014 Feb;42(2):313-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24105455
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2018 Jan 30;10(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29385696
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Methods Mol Biol. 2019;1878:243-261
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30378081
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2011 Apr;90(1):64-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21356245
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2016 Jan 4;44(D1):D1069-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26578601
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Jan 23;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31971553
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Comput Biol. 2016 Sep 15;12(9):e1005074
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27632082
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2016 Jul 7;535(7610):169-172
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27362232
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Cancer. 2008 Jan;8(1):24-36
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18097462
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Brief Bioinform. 2017 Jul 1;18(4):682-697
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27296652
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2015 May 14;372(20):1877-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25970049
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2015 Feb;59(2):1088-99
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25487801
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Pathog. 2014 May 22;10(5):e1004163
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24852294
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viral Immunol. 2008 Jun;21(2):153-62
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18433331
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antiviral Res. 2018 Feb;150:123-129
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29258862
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS One. 2018 Mar 22;13(3):e0194868
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29566060
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2006 Sep 29;313(5795):1929-35
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17008526
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMC Immunol. 2005 Jan 18;6:2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15655079
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation indexingmethod="Curated" owner="NLM" status="MEDLINE">
     <pmid version="1">
      32194944
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       03
      </month>
      <day>
       24
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       03
      </month>
      <day>
       27
      </day>
     </daterevised>
     <article pubmodel="Electronic-eCollection">
      <journal>
       <issn issntype="Electronic">
        2046-1402
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         9
        </volume>
        <pubdate>
         <year>
          2020
         </year>
        </pubdate>
       </journalissue>
       <title>
        F1000Research
       </title>
       <isoabbreviation>
        F1000Res
       </isoabbreviation>
      </journal>
      <articletitle>
       Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL
       <sup>
        pro
       </sup>
       ) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.
      </articletitle>
      <pagination>
       <medlinepgn>
        129
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.12688/f1000research.22457.1
      </elocationid>
      <abstract>
       <abstracttext>
        We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL
        <sup>
         pro
        </sup>
        ) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart.  With the 3CL
        <sup>
         pro
        </sup>
        molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache.  The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes.
       </abstracttext>
       <copyrightinformation>
        Copyright: © 2020 Chen YW et al.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Yu Wai
        </forename>
        <initials>
         YW
        </initials>
        <identifier source="ORCID">
         0000-0001-7833-7533
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Applied Biology &amp; Chemical Technology, Hong Kong Polytechnic University, Hunghom, Hong Kong.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          State Key Laboratory of Chemical Biology and Drug Discovery, Hunghom, Hong Kong.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yiu
        </lastname>
        <forename>
         Chin-Pang Bennu
        </forename>
        <initials>
         CB
        </initials>
        <identifier source="ORCID">
         0000-0003-3965-3992
        </identifier>
        <affiliationinfo>
         <affiliation>
          Independent Researcher, La Costa, Ma On Shan, Hong Kong.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wong
        </lastname>
        <forename>
         Kwok-Yin
        </forename>
        <initials>
         KY
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Applied Biology &amp; Chemical Technology, Hong Kong Polytechnic University, Hunghom, Hong Kong.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          State Key Laboratory of Chemical Biology and Drug Discovery, Hunghom, Hong Kong.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D013485">
        Research Support, Non-U.S. Gov't
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        21
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       F1000Res
      </medlineta>
      <nlmuniqueid>
       101594320
      </nlmuniqueid>
      <issnlinking>
       2046-1402
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D001562">
        Benzimidazoles
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D002219">
        Carbamates
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D005449">
        Fluorenes
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D006576">
        Heterocyclic Compounds, 4 or More Rings
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D017361">
        Viral Nonstructural Proteins
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D014764">
        Viral Proteins
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        013TE6E4WV
       </registrynumber>
       <nameofsubstance ui="C586541">
        ledipasvir
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.22.-
       </registrynumber>
       <nameofsubstance ui="D003546">
        Cysteine Endopeptidases
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        KCU0C7RS7Z
       </registrynumber>
       <nameofsubstance ui="C000604171">
        velpatasvir
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D001562">
        Benzimidazoles
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D002219">
        Carbamates
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D003546">
        Cysteine Endopeptidases
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058492">
        Drug Repositioning
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D005449">
        Fluorenes
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006576">
        Heterocyclic Compounds, 4 or More Rings
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D017361">
        Viral Nonstructural Proteins
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D014764">
        Viral Proteins
       </descriptorname>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="Y">
       3C-like protease
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       HCV
      </keyword>
      <keyword majortopicyn="Y">
       Hepatitis C virus
      </keyword>
      <keyword majortopicyn="Y">
       SARS
      </keyword>
      <keyword majortopicyn="Y">
       antiviral
      </keyword>
      <keyword majortopicyn="Y">
       coronavirus
      </keyword>
      <keyword majortopicyn="Y">
       drug repurpose
      </keyword>
      <keyword majortopicyn="Y">
       ledipasvir
      </keyword>
      <keyword majortopicyn="Y">
       molecular modelling
      </keyword>
      <keyword majortopicyn="Y">
       velpatasvir
      </keyword>
      <keyword majortopicyn="Y">
       virtual screening
      </keyword>
     </keywordlist>
     <coistatement>
      No competing interests were disclosed.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        02
       </month>
       <day>
        19
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        21
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        21
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        25
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32194944
      </articleid>
      <articleid idtype="doi">
       10.12688/f1000research.22457.1
      </articleid>
      <articleid idtype="pmc">
       PMC7062204
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Biochemistry. 2010 May 25;49(20):4308-17
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20420403
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virology. 2009 Jun 5;388(2):324-34
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19409595
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Bioorg Med Chem. 2004 May 15;12(10):2517-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15110833
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Med. 2006 Sep;3(9):e343
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16968120
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proteins. 2000 Aug 15;40(3):389-408
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         10861930
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        F1000Res. 2020 Feb 21;9:129
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32194944
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 5;382(10):929-936
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32004427
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):12997-13002
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27799534
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Comput Chem. 2010 Jan 30;31(2):455-61
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19499576
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Genet Genomics. 2020 Feb 13;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32173287
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Theor Biol. 2008 Oct 21;254(4):861-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18706430
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2005 Sep 2;280(35):31257-66
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15788388
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Chem. 2016 Jul 28;59(14):6595-628
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26878082
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochemistry. 2004 Apr 20;43(15):4568-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15078103
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841273
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):514-523
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986261
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15226499
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2004 Mar;59(3):252-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14985565
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proteins. 2009 Dec;77(4):778-95
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19603484
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nucleic Acids Res. 2015 Jul 1;43(W1):W448-54
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25855812
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biochem. 2008 Apr;143(4):525-36
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18182387
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochemistry. 2006 Dec 19;45(50):14908-16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17154528
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32179150
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       02
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1872-7913
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        International journal of antimicrobial agents
       </title>
       <isoabbreviation>
        Int. J. Antimicrob. Agents
       </isoabbreviation>
      </journal>
      <articletitle>
       Teicoplanin: an alternative drug for the treatment of COVID-19?
      </articletitle>
      <pagination>
       <medlinepgn>
        105944
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0924-8579(20)30094-7
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.ijantimicag.2020.105944
      </elocationid>
      <abstract>
       <abstracttext>
        In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find a therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin and ritonavir have shown efficacy to inhibit coronavirus in vitro. Teicoplanin, an antibiotic used to treat staphylococcal infections, previously showed efficacy to inhibit the first stage of the Middle East respiratory syndrome coronavirus (MERS-CoV) viral life cycle in human cells. This activity is conserved against SARS-Cov-2, thus placing teicoplanin as a potential treatment for patients with this virus.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Baron
        </lastname>
        <forename>
         Sophie Alexandra
        </forename>
        <initials>
         SA
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Devaux
        </lastname>
        <forename>
         Christian
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, IRD, APHM, VITROME, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Colson
        </lastname>
        <forename>
         Philippe
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Raoult
        </lastname>
        <forename>
         Didier
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rolain
        </lastname>
        <forename>
         Jean-Marc
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Aix-Marseille Université, IRD, APHM, MEPHI, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France; IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13385 Marseille Cedex 05, France. Electronic address: jean-marc.rolain@univ-amu.fr.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       Int J Antimicrob Agents
      </medlineta>
      <nlmuniqueid>
       9111860
      </nlmuniqueid>
      <issnlinking>
       0924-8579
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Drug repurposing
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       Teicoplanin
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        04
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        09
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32179150
      </articleid>
      <articleid idtype="pii">
       S0924-8579(20)30094-7
      </articleid>
      <articleid idtype="doi">
       10.1016/j.ijantimicag.2020.105944
      </articleid>
      <articleid idtype="pmc">
       PMC7102624
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32149769
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2542-5641
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
         <day>
          06
         </day>
        </pubdate>
       </journalissue>
       <title>
        Chinese medical journal
       </title>
       <isoabbreviation>
        Chin. Med. J.
       </isoabbreviation>
      </journal>
      <articletitle>
       Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1097/CM9.0000000000000797
      </elocationid>
      <abstract>
       <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
        Medicines for the treatment of 2019-novel coronavirus (2019-nCoV) infections are urgently needed. However, drug screening using live 2019-nCoV requires high-level biosafety facilities, which imposes an obstacle for those without such facilities or 2019-novel coronavirus (2019-nCoV). This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 (COVID-19) in a 2019-nCoV related coronavirus model.
       </abstracttext>
       <abstracttext label="METHODS" nlmcategory="METHODS">
        A 2019-nCoV related pangolin coronavirus GX_P2V/pangolin/2017/ Guangxi was described. Whether GX_P2X uses angiotensin-converting enzyme 2 (ACE2) as the cell receptor was investigated by using small interfering RNA (siRNA) -mediated silencing of ACE2. The pangolin coronavirus model was used to identify drug candidates for treating 2019-nCoV infection. Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic effects on Vero E6 cells by GX_P2X infection. The antiviral activities and antiviral mechanisms of potential drugs were further investigated. Viral yields of RNAs and infectious particles were quantified by quantitative real-time polymerase chain reaction (qRT-PCR) and plaque assay, respectively.
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        The spike protein of coronavirus GX_P2V shares 92.2% amino acid identity with that of 2019-nCoV isolate Wuhan-hu-1, and uses ACE2 as the receptor for infection just like 2019-nCoV. Three drugs-cepharanthine (CEP), selamectin and mefloquine hydrochloride exhibited complete inhibition of cytopathic effects in cell culture at 10 μmol/L. CEP demonstrated the most potent inhibition of GX_P2V infection, with a concentration for 50% of maximal effect [EC50] of 0.98 μmol/L. The viral RNA yield in cells treated with 10 μmol/L CEP was 15,393-fold lower than in cells without CEP treatment ([6.48 ± 0.02] × 10vs. 1.00 ± 0.12, t = 150.38, P &lt; 0.001) at 72 h post-infection (p.i.). Plaque assays found no production of live viruses in media containing 10 μmol/L CEP at 48 h p.i. Furthermore, we found CEP has potent antiviral activities against both viral entry (1.00 ± 0.37 vs. 0.46 ± 0.12, t = 2.42, P &lt; 0.05) and viral replication (1.00 ± 0.43 vs. [6.18 ± 0.95] × 10, t = 3.98, P &lt; 0.05).
       </abstracttext>
       <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
        Our pangolin coronavirus GX_P2V is a workable model for 2019-nCoV research. CEP, selamectin and mefloquine hydrochloride are potential drugs for treating 2019-nCoV infection. Our results strongly suggest that CEP is a wide-spectrum inhibitor of pan-betacoronavirus, and clinical trial of CEP for treatment of 2019-nCoV infection is warranted.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Fan
        </lastname>
        <forename>
         Hua-Hao
        </forename>
        <initials>
         HH
        </initials>
        <affiliationinfo>
         <affiliation>
          Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Li-Qin
        </forename>
        <initials>
         LQ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Wen-Li
        </forename>
        <initials>
         WL
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         An
        </lastname>
        <forename>
         Xiao-Ping
        </forename>
        <initials>
         XP
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Zhen-Dong
        </forename>
        <initials>
         ZD
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         He
        </lastname>
        <forename>
         Xiao-Qi
        </forename>
        <initials>
         XQ
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Song
        </lastname>
        <forename>
         Li-Hua
        </forename>
        <initials>
         LH
        </initials>
       </author>
       <author validyn="Y">
        <lastname>
         Tong
        </lastname>
        <forename>
         Yi-Gang
        </forename>
        <initials>
         YG
        </initials>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        06
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Chin Med J (Engl)
      </medlineta>
      <nlmuniqueid>
       7513795
      </nlmuniqueid>
      <issnlinking>
       0366-6999
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        3
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32149769
      </articleid>
      <articleid idtype="doi">
       10.1097/CM9.0000000000000797
      </articleid>
      <articleid idtype="pmc">
       PMC7147283
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Bioorg Med Chem Lett. 2014 May 1;24(9):2115-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24704028
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chin Med J (Engl). 2005 Mar 20;118(6):493-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15788131
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2003 Nov 27;426(6965):450-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14647384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2013 Nov 28;503(7477):535-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24172901
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chin J Cancer. 2014 May;33(5):223-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24103790
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Anal Biochem. 2013 Mar 1;434(1):202-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23219559
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biomolecules. 2019 Nov 04;9(11):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31690059
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2017 Jun 9;91(13):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28404852
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Rep. 2011;63(2):337-47
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21602589
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):265-269
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015508
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24841273
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):270-273
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2019 Oct 24;11(11):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31652964
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar 26;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32218527
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
  </pubmedarticleset>
 </body>
</html>